Phase 4 Pharmacovigilance
Continuous post-approval safety surveillance with India-specific pharmacogenomic signal detection. Anchored on the Apollo EHR pipeline and the agentic QC/Validator. Recurring contract structure — the highest-margin recurring revenue line in the offerings stack. Pairs with the IVD CDx sprint as our second flagship reference program.
The customer scenario
A pharma has an approved drug — say, a DOAC (apixaban) or a CV/diabetes combination — sold at scale in India. They need Phase 4 real-world safety surveillance with pharmacogenomic signal detection. India-specific PGx variants (CYP2C9, VKORC1, CYP2C19) make Western label data structurally insufficient. Traditional path: contract a Phase 4 CRO study with manual ADR reporting + claims data — $10–30M, 3–5 years, weak India-specific signal.
Example signal: CYP2C19 and clopidogrel
In South Indian populations, CYP2C19 poor-metabolizer frequency is materially higher than in European cohorts. A Western-derived label may under-state bleeding or efficacy failure risk. Our Apollo EHR feed + PGx sub-cohort characterizes ADR experiencers against Atlas baselines — surfacing actionable signals quarters earlier than manual pharmacovigilance.
Program components
| Component | LabOS execution | Annual cost |
|---|---|---|
| Real-world evidence feed | Continuous DPDP-compliant pipeline from Apollo EHR (de-identified, federated). Patient-on-drug cohort sized at 5K–50K depending on indication. | $0.6M |
| Multiomics sub-cohort | ADR experiencers (~2–5% of treated) characterized via WGS + targeted PGx panel + metabolomics. Agentic anomaly detection over the Atlas baseline. | $1.2M |
| Signal detection | QC + Learning Agents continuously refine signal-to-noise. Quarterly signal reports with PGx + ethnicity stratification. Auto-generated CIOMS-format ADR narratives. | $0.4M |
| Regulatory packaging | ClinicalBridge quarterly PSUR/PBRER inputs for CDSCO + label-update support packages for FDA/EMA when actionable signal emerges. | $0.3M |
| Total recurring | 12–18 month contracts, renew annually | $2.5M/yr vs. $10–30M one-off |
Revenue to us
- $2–4M/year active surveillance contract (recurring, high gross margin)
- $250K–1M per actionable signal (label-update support package)
- Bundle pricing across a pharma's portfolio (5+ drugs = 30%+ discount, 10× ACV)
- Atlas enrichment — every PV cohort feeds the Atlas with longitudinal phenotype data
- Apollo revenue share: 20–30% of surveillance contract value
Why this works for the pharma buyer
- Recurring revenue model aligned to pharma's PV budget cycle — easy to procure
- India-specific PGx signals not extractable from US/EU databases
- Auto-generated CIOMS narratives cut PV writing cost by 60–80%
- Audit-ready — provenance-signed every step; survives CDSCO + FDA inspection
- Pre-emptive label refinement protects post-marketing revenue from withdrawal risk
Renewal & expansion
Year 1 contract → annual renewal with Atlas enrichment uplift. Portfolio bundles across 5+ SKUs. Cross-sell to IVD CDx when stratification biomarkers emerge from PV signals.